Votrient: first targeted oral therapy for advanced soft tissue sarcoma

Votrient (pazopanib) has been approved as a treatment option for advanced soft tissue sarcoma (STS).

Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.
Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.

The tyrosine kinase inhibitor is indicated to treat selected subtypes of the disease in adults who have received prior chemotherapy for metastatic disease or who have progressed within 12 months of neo-adjuvant therapy.

Votrient is already licensed for the first-line treatment of adults with renal cell carcinoma (RCC) and for RCC patients who have received prior cytokine therapy for advanced disease.

Increased survival

The efficacy and safety of pazopanib in STS were assessed in a randomised, double-blind, placebo controlled, multicentre, phase III study (PALETTE) involving 369 patients with certain subtypes of advanced STS who had previously received chemotherapy.

Pazopanib 800mg once daily significantly increased median progression-free survival to 4.6 months, compared with 1.6 months for placebo (HR=0.31 [95% CI: 0.24–-0.40]; p<0.0001).

Adverse events identified in this advanced STS population that had not previously been seen in advanced RCC patients included venous thromboembolic events and pneumothorax.

View Votrient drug record

Further information: GSK

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases